Healthcare Entrepreneurship and Venture Panel

 
 

“Investing in Novel Technologies and System Enhancements to Improve Health Outcomes”

SAMPLE ISSUES

  • What novel technologies and systems enhancements (life science and healthcare services/IT) are venture firms currently supporting to improving health outcomes and reduce healthcare costs?
  • Payment reform, in all of its possible forms-- value-based purchasing, readmission penalties, bundled payments, and shared savings—will dramatically affect the relationship between payers, providers, and industry participants. What opportunities does this create for venture capitalists and entrepreneurs?
  • Wellness and chronic disease management represents a key area of convergence between the healthcare services, life sciences and pharma communities. What are the most attractive new developments in this space for investors?
  • What are some best practices by VC firms in identifying, evaluating, and negotiating new venture investments, including key inflection points to maximize value?
  • What are the most salient lessons learned by “serial entrepreneurs” in creating and managing early-stage life science and healthcare services companies, including working with VCs and Angel investors, and capital formation and partnering strategies?

David Tamburri
Partner
Health Enterprise Partners

David is a General Partner with Health Enterprise Partners, L.P. (HEP), a growth equity fund focused exclusively on healthcare services and information technology companies. Prior to joining HEP, David was a VP with Susquehanna Growth Equity, a private equity group focused on growth capital opportunities in the technology sector. He was formerly the President and COO at Onward Healthcare, Inc., a provider of human capital services to healthcare providers sponsored by Welsh, Carson, Anderson, & Stowe.  As an EVP with Pinnacor, Inc., a provider of information and analytical applications, David managed the company’s worldwide operations. Pinnacor completed an IPO in 2000 and was later sold to CBS Marketwatch.

David is on the boards of eVariant, Privia Health, and Summetria. He is a board observer at MDx Medical. He was a director of MobileMD prior to the company's sale to Siemens. He serves on the Advisory Board of the NYC Health Business Leaders and on the board of The Open Door Shelter. Since 2000, David has been a Lecturer at Columbia University in the Executive Master of Science in Technology Management program.

He is a distinguished graduate of the United States Military Academy and holds an MBA from Harvard Business School.

Tamara Elias, MD
Partner
Essex Woodlands

Tamara Elias, M.D. is a Partner at Essex Woodlands, a global health care-only growth equity firm with $2.5B under management. She brings nearly 20 years of healthcare experience to the Firm, which she joined in 2007. Essex is currently investing Fund VIII of $900 million, where Dr. Elias is involved in deal sourcing, evaluation and execution across the U.S. as well as providing ongoing support to portfolio companies.

Dr. Elias currently serves on the Boards of Millennium Pharmacy Systems, a technology based long term care pharmacy, BreatheAmerica which oversees outpatient clinics focused on the management of chronic airway diseases, as well as Medseek, the leading provider of online strategic patient engagement solutions for hospitals. Previously she served on the board of ATS Medical, which was sold to Medtronic for $370 million in 2010. 

Prior to Essex, Dr. Elias spent six years at McKinsey as a senior engagement manager and was a general surgery resident at Massachusetts General Hospital after receiving her M.D. at Johns Hopkins School of Medicine. She received her B.A. from Yale University. 

Dr. Elias is also an organizing member of MedtechWomen for women leaders in the industry, which hosts an annual MedtechVision conference to discuss the most challenging issues facing the sector and propose solutions. She is also a Kauffman Venture Fellow.

Bill Goldberg
CEO

MediMedia

William Goldberg is CEO of MediMedia, a provider of patient education and consumer health information, outsourced pharmaceutical sales and marketing support services and comprehensive health management programs. Bill also serves as Chairman of the Board of DNA Diagnostic Center, Inc..  Prior to joining MediMedia, Bill was CEO of Planet Pharmaceuticals, a manufacturer and developer of allergy immunotherapy drugs and multi-channel marketer of related products. Previously, he was President of Morton Grove Pharmaceuticals, a manufacturer of liquid generic pharmaceuticals. Prior to joining that company, Bill held senior management and board positions at Lifecare Holdings, an operator of long term acute care hospitals, and TransHealthcare, an operator of skilled nursing facilities. Earlier in his career, Bill worked with a private equity fund focused on buying, repairing and building underperforming businesses. Bill holds a Bachelor of Arts degree from Brown University and a Masters of Business Administration degree from The Wharton School, University of Pennsylvania.

Mitch Rothschild '79
CEO

Vitals

Mitch brings two decades of entrepreneurial experience to his role as co-founder, Chief Perfectionist & CEO of Vitals. Prompted by personal medical experience that could have turned out badly, Mitch helped found Vitals. He designs and oversees the direction of the company and promulgates the Vitals message to the world.

Prior to Vitals, Mitch founded RaspberryRed Marketing, NetWorks, Tuff Rhino, Awards.com, RUSS CandyBears and Time Warner Viewer’s Edge. He has also been involved in the rapid growth of Popcorn Indiana, Blue Moon Mexican Cafe and IT’SUGAR. 

Mitch has an MBA, with honors, from Columbia University and an MA (Phi Beta Kappa, Summa Cum Laude) from Queens College.

Andrew Schiff, MD ’00
Managing Partner
Aisling Capital

Andrew Schiff is a Managing Partner of Aisling Capital, a healthcare focused private equity investment firm.  Previously, he practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as Clinical Assistant Professor of Medicine.  In his capacity at Aisling Capital, he serves and has served on the boards of a number of public and private healthcare companies, including Adams Respiratory Therapeutics, Myogen, Zeltiq Aesthetics, and SkinMedica.  He is a long-time supporter of the Visiting Nurse Service of New York as well as other charitable organizations. Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University, and his Sc.B. with honors in Neuroscience from Brown University.